Diabetologia:双羰基胁迫与补体激活的关系?

2020-07-20 MedSci原创 MedSci原创

活性α-dicarbonyl化合物α-二羰基化合物是AGEs的主要前体,可能导致循环和/或细胞相关的补体调节剂糖化。补体调节蛋白的糖基化可影响其抑制补体激活的能力。

活性α-dicarbonyl化合物α-二羰基化合物是AGEs的主要前体,可能导致循环和/或细胞相关的补体调节剂糖化。补体调节蛋白的糖基化可影响其抑制补体激活的能力。 我们在一个人类队列中研究了二羰基应激是否与更多的补体激活有关。

研究人员在马斯特里赫特队列研究(CODAM)的530名参与者(59.5岁±7.0岁[平均±SD],61%的男性)测量了循环浓度的二羰基应激标志物,即α-二羰基(甲基乙二醛[MGO],乙二醛[GO]和3-脱氧葡糖酮[3-DG])和游离AGEs(Nε-(羧甲基)赖氨酸[CML],Nε-(羧乙基) )赖氨酸[CEL]和Nδ-(5-氢-5-甲基-4-咪唑啉-2-基)-鸟氨酸[MG-H1]),以及与蛋白质结合的AGEs(CML,CEL,戊糖苷),补体激活产物C3a和可溶性C5b-9(sC5b-9)等指标。采用多元线性回归分析研究了双羰基压力(标准化)和补体激活(标准化)与潜在混杂因素(包括年龄、性别、生活方式、药物使用和肥胖标记)之间的关系。此外,我们还评估了两种潜在功能多态性(rs1049346、rs2736654)在编码甘草酸酶1 (GLO1)的基因、MGO的限速解毒酶与C3a和sC5b-9(均为标准化)的关联。

研究结果显示,在调整潜在的混杂因素后,血浆浓度的二羰基与sC5b-9负相关(β−0.12 (95% CI -0.21−0.02)),结合蛋白的AGE CEL与C3a呈负相关(-0.17 [-0.25,-0.08])。 相反,与蛋白质结合的AGE Pentosidine与sC5b-9正相关(0.15 [0.05,0.24])。 没有观察到其他α-二羰基和其他游离或蛋白结合的AGEs与C3a或sC5b-9的关联。 具有rs1049346的AG和AA基因型的个体的sC5b-9血浆浓度平均比具有GG基因型的个体低0.32和0.40 SD,而C3a的浓度在rs1049346基因型之间没有显着差异。 GLO1 rs2736654与C3a或sC5b-9没有关联。

研究结果表明,血浆中二羰基压力标记物的浓度与补体激活产物有明显的相关性,具体为其中一些与C3a或sC5b-9呈负相关,而与蛋白质结合的戊糖定与sC5b-9呈一致的正相关。这表明了不同的生物学关系的个别二羰基应激标记与补体的激活。

原始出处:

Ying Xin, Elisabeth Hertle,Associations of dicarbonyl stress with complement activation: the CODAM study

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1761450, encodeId=8fc31e614505e, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Jul 26 00:19:22 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639526, encodeId=1d8b1639526ed, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Nov 12 11:19:22 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=808319, encodeId=3a42808319b6, content=😊😊😊, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04615119581, createdName=14631baam13暂无昵称, createdTime=Thu Aug 13 06:51:10 CST 2020, time=2020-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592087, encodeId=9d81159208e19, content=<a href='/topic/show?id=f7b7901238d' target=_blank style='color:#2F92EE;'>#补体激活#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90123, encryptionId=f7b7901238d, topicName=补体激活)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63f218082312, createdName=sodoo, createdTime=Wed Jul 22 05:19:22 CST 2020, time=2020-07-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1761450, encodeId=8fc31e614505e, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Jul 26 00:19:22 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639526, encodeId=1d8b1639526ed, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Nov 12 11:19:22 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=808319, encodeId=3a42808319b6, content=😊😊😊, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04615119581, createdName=14631baam13暂无昵称, createdTime=Thu Aug 13 06:51:10 CST 2020, time=2020-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592087, encodeId=9d81159208e19, content=<a href='/topic/show?id=f7b7901238d' target=_blank style='color:#2F92EE;'>#补体激活#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90123, encryptionId=f7b7901238d, topicName=补体激活)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63f218082312, createdName=sodoo, createdTime=Wed Jul 22 05:19:22 CST 2020, time=2020-07-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1761450, encodeId=8fc31e614505e, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Jul 26 00:19:22 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639526, encodeId=1d8b1639526ed, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Nov 12 11:19:22 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=808319, encodeId=3a42808319b6, content=😊😊😊, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04615119581, createdName=14631baam13暂无昵称, createdTime=Thu Aug 13 06:51:10 CST 2020, time=2020-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592087, encodeId=9d81159208e19, content=<a href='/topic/show?id=f7b7901238d' target=_blank style='color:#2F92EE;'>#补体激活#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90123, encryptionId=f7b7901238d, topicName=补体激活)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63f218082312, createdName=sodoo, createdTime=Wed Jul 22 05:19:22 CST 2020, time=2020-07-22, status=1, ipAttribution=)]
    2020-08-13 14631baam13暂无昵称

    😊😊😊

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1761450, encodeId=8fc31e614505e, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Sun Jul 26 00:19:22 CST 2020, time=2020-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639526, encodeId=1d8b1639526ed, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Thu Nov 12 11:19:22 CST 2020, time=2020-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=808319, encodeId=3a42808319b6, content=😊😊😊, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04615119581, createdName=14631baam13暂无昵称, createdTime=Thu Aug 13 06:51:10 CST 2020, time=2020-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1592087, encodeId=9d81159208e19, content=<a href='/topic/show?id=f7b7901238d' target=_blank style='color:#2F92EE;'>#补体激活#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90123, encryptionId=f7b7901238d, topicName=补体激活)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=63f218082312, createdName=sodoo, createdTime=Wed Jul 22 05:19:22 CST 2020, time=2020-07-22, status=1, ipAttribution=)]

相关资讯

Blood:多反应性IgM通过PF4/肝素复合物激活经典信号通路启动补体激活

中心点:多反应性IgM通过PF4/肝素复合物激活经典信号通路介导补体活化。在健康供者中,PF4/肝素复合物的补体激活存在很大差异。摘要:多种(如果不是大部分)受体暴露于肝素所引发的抗体反应的机制尚不明确。Sanjay Khandelwal等人近期发现抗原血小板因子4(PF4)/肝素复合物可激活血浆中的补体,并与B细胞结合,其对该过程是如何起始进行了深入研究。当研究人员将PF4/肝素复合物加入健康供

Sci Rep:良性前列腺增生生长过程中通过自身抗原识别的补体激活研究

良性前列腺增生(BPH)的病理生理机制仍旧不清楚。最近,有研究人员利用小鼠模型聚焦了BHP生长过程中的补体激活过程。研究人员从进行了小鼠泌尿生殖窦植入术的小鼠中获取了BPH组织,并通过实时定量RT-PCR、蛋白免疫印迹和免疫组化技术(IHC)分析了小鼠和人类BPH组织中C1q、C3、甘露糖结合凝集素(MBL)、因子B (FB)和C5b-9的局部表达和累积水平,还利用ELISA和IHC分别分析了血清